SCYNEXIS (SCYX) Stock Price
SCYNEXIS Price
Revenue at SCYNEXIS has contracted by 11.8% per year over the past 12 years to 3.75 M USD. SCYNEXIS's net margin stands at -568.3%, up from -44,758.3% several years earlier. Analysts set a median price target of 4.08 USD, implying 21.8% below the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 43% above its 52-week low.
SCYNEXIS stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of SCYNEXIS over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how SCYNEXIS stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing SCYNEXIS's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | SCYNEXIS Price |
|---|---|
| 9/2/2026 | 5.22 USD |
| 9/1/2026 | 5.17 USD |
| 8/31/2026 | 5.23 USD |
| 8/30/2026 | 5.48 USD |
| 8/28/2026 | 5.46 USD |
| 8/27/2026 | 5.44 USD |
| 8/26/2026 | 5.67 USD |
| 8/25/2026 | 5.19 USD |
| 8/24/2026 | 5.18 USD |
| 8/21/2026 | 5.10 USD |
| 8/20/2026 | 5.22 USD |
| 8/19/2026 | 5.30 USD |
| 8/18/2026 | 5.09 USD |
| 8/17/2026 | 5.09 USD |
| 8/14/2026 | 5.18 USD |
| 8/13/2026 | 5.12 USD |
| 8/12/2026 | 4.79 USD |
| 8/10/2026 | 5.16 USD |
| 8/7/2026 | 5.24 USD |
| 8/6/2026 | 5.20 USD |
| 8/5/2026 | 5.11 USD |
| 8/4/2026 | 5.28 USD |
| 8/3/2026 | 5.07 USD |
| 7/31/2026 | 4.84 USD |
| 7/30/2026 | 3.73 USD |
| 7/29/2026 | 3.65 USD |
| 7/27/2026 | 3.66 USD |
| 7/23/2026 | 3.96 USD |
| 7/22/2026 | 3.95 USD |
| 7/21/2026 | 4.05 USD |
SCYNEXIS Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
SCYNEXIS Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | 13.00 | 5.00 | 140.00 | 3.00 | 10.00 | 39.00 | 2.00 | 14.00 | 14.00 | 40.00 | 67.00 |
| – | – | – | – | – | – | -61.54 | 2,700.00 | -97.86 | 233.33 | 290.00 | -94.87 | 600.00 | – | 185.71 | 67.50 |
| – | – | – | – | – | 92.31 | 80.00 | 88.57 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 12.00 | 4.00 | 124.00 | 3.00 | 10.00 | 39.00 | 2.00 | 14.00 | 14.00 | 40.00 | 67.00 |
| -27.00 | -26.00 | -29.00 | -48.00 | -51.00 | -60.00 | -85.00 | 72.00 | -37.00 | -29.00 | -3.00 | -28.00 | -19.00 | -23.00 | -2.00 | – |
| – | – | – | – | – | -461.54 | -1,700.00 | 51.43 | -1,233.33 | -290.00 | -7.69 | -1,400.00 | -135.71 | -164.29 | -5.00 | – |
| -29.00 | -25.00 | -12.00 | -53.00 | -55.00 | -32.00 | -62.00 | 67.00 | -21.00 | -16.00 | -2.00 | -18.00 | -12.00 | -15.00 | 32.00 | – |
| -9.38 | -13.79 | -52.00 | 341.67 | 3.77 | -41.82 | 93.75 | -208.06 | -131.34 | -23.81 | -87.50 | 800.00 | -33.33 | 25.00 | -313.33 | – |
| 1.90 | 2.67 | 4.39 | 5.61 | 10.72 | 26.38 | 42.61 | 48.39 | 48.51 | 48.51 | 48.51 | 48.51 | 48.51 | 48.51 | 48.51 | 48.51 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales SCYNEXIS generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue SCYNEXIS retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare SCYNEXIS's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares SCYNEXIS has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against SCYNEXIS's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
SCYNEXIS stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
SCYNEXIS Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
SCYNEXIS business model & stock analysis
SCYNEXIS SWOT Analysis
Strengths
1. Innovative Research Capabilities: SCYNEXIS Inc possesses a strong R&D team and cutting-edge technologies, allowing them to develop novel pharmaceutical products.
2. Solid Financial Position: The company enjoys a healthy financial state, with sufficient reserves to support its ongoing operations and potential growth opportunities.
3. Diverse Product Portfolio: SCYNEXIS Inc has a wide range of product offerings, spanning different therapeutic areas, which reduces dependency on a single product.
Weaknesses
1. Dependency on Key Partners: SCYNEXIS Inc relies heavily on strategic partnerships for product development and commercialization, which exposes them to potential risks if these relationships falter.
2. Limited Market Presence: The company faces stiff competition from established pharmaceutical giants, which may limit its market reach and customer base.
3. Regulatory Challenges: SCYNEXIS Inc operates in a highly regulated industry. Compliance with strict regulatory standards and obtaining necessary approvals can be time-consuming and expensive.
Opportunities
1. Market Expansion: SCYNEXIS Inc can explore new markets globally, expanding its presence beyond its current geographical footprint and tapping into untapped customer segments.
2. Technological Advancements: Advancements in technology, such as artificial intelligence and genomic research, present opportunities for SCYNEXIS Inc to enhance their drug discovery and development processes.
3. Increasing Healthcare Spending: With rising healthcare expenditures worldwide, the demand for innovative and effective pharmaceutical products is expected to grow, providing an opportunity for SCYNEXIS Inc to capture a larger market share.
Threats
1. Intense Competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share. SCYNEXIS Inc faces the risk of being outperformed or overshadowed by larger competitors.
2. Patent Expirations: The expiration of patents for existing drugs can lead to generic competition, potentially impacting sales and market share for SCYNEXIS Inc.
3. Economic Volatility: Economic downturns and fluctuations can adversely affect overall healthcare spending, leading to reduced demand for pharmaceutical products and impacting the company's revenue.
SCYNEXIS Segments
SCYNEXIS Revenue by Segment
3 Years
5 Years
Max
Details
SCYNEXIS Revenue by Region
3 Years
5 Years
10 Years
Max
Details
SCYNEXIS Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
SCYNEXIS historical P/E ratio, EBIT multiple, and P/S ratio
SCYNEXIS annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
SCYNEXIS shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
SCYNEXIS stock splits
Current SCYNEXIS forecasts and price targets in September 2026
Analyst Price Targets 2026SCYNEXIS Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/17/2026 | -0.52USD | - | 0.00USD | - | 2026 Q2 |
| 5/13/2026 | -0.13USD | - | 0.00USD | - | 2026 Q1 |
| 3/10/2026 | 0.13USD | - | 8.26 MUSD | - | 2025 Q4 |
| 11/11/2024 | -0.08USD | - | 6.31 MUSD | - | 2024 Q3 |
| 5/8/2024 | -0.01USD | - | 11.41 MUSD | - | 2024 Q1 |
| 3/29/2024 | -0.20USD | - | 1.40 MUSD | - | 2023 Q4 |
| 11/7/2023 | -0.21USD | - | 3.18 MUSD | - | 2023 Q3 |
| 8/14/2023 | -0.35USD | - | 4.17 MUSD | - | 2023 Q2 |
| 5/10/2023 | -0.38USD | - | 2.92 MUSD | - | 2023 Q1 |
| 3/27/2023 | -0.43USD | - | 2.54 MUSD | - | 2022 Q4 |
SCYNEXIS shareholder structure
| % | Name |
|---|---|
12.19108% | |
0.84770% | |
0.58599% | |
0.23707% | |
0.12592% | |
0.03574% |
SCYNEXIS Executives and Management Board
10 members · avg. age 64 · 20 % women
Dr. David Angulo (60)
President, Chief Executive Officer, Director · since 2015
2.03 M USD
Management
Mr. Ivor Macleod (64)
Chief Financial Officer
Mr. Scott Sukenick (47)
Chief Legal Officer, General Counsel
Ms. Irina Koffler
Investor Relations · since 2021
Board of Directors
Mr. Guy Macdonald (66)
Non-Executive Independent Chairman of the Board
Dr. Steven Gilman (72)
Independent Director
Dr. Ann Hanham (72)
Independent Director
Mr. David Hastings (63)
Independent Director
Mr. Armando Anido (67)
Independent Director
Mr. Philippe Tinmouth (61)
Independent Director
SCYNEXIS Supply Chain
SCYNEXIS Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.78 | 0.73 | 0.66 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.81 | -0.69 | -0.71 | ||
| 2 | 0.41 | -0.06 | -0.05 |
Frequently asked questions about SCYNEXIS
The business model of SCYNEXIS Inc. revolves around the development and commercialization of innovative therapies to address unmet medical needs. As a biotechnology company, SCYNEXIS focuses on discovering and developing novel anti-infectives, including antifungals, to combat life-threatening and serious fungal infections. By leveraging its expertise in chemistry, microbiology, and clinical development, SCYNEXIS aims to provide effective and safe treatment options for patients. With a strong commitment to research and development, SCYNEXIS strives to improve patient outcomes and make a significant impact in the field of infectious diseases.
SCYNEXIS Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of SCYNEXIS Inc in the market are various pharmaceutical companies that specialize in the development of antifungal drugs. Some notable competitors include Pfizer Inc, Merck & Co. Inc, Novartis AG, and Johnson & Johnson. These companies also focus on researching and producing solutions for fungal infections. SCYNEXIS Inc competes in this dynamic market by leveraging its innovative antifungal portfolio, unique research approaches, and commitment to bridging unmet medical needs. By actively participating in the competitive landscape, SCYNEXIS Inc continues to ensure that patients have access to effective antifungal treatments.
SCYNEXIS Inc is a biotechnology company based in New Jersey, United States. Established in 1999, it specializes in the research and development of novel anti-infectives, including antifungal therapies. The company focuses on delivering innovative solutions to combat serious and life-threatening fungal infections. With a team of experienced scientists and a strong commitment to scientific excellence, SCYNEXIS Inc has made significant advancements in the field of antifungal drug discovery. By leveraging its proprietary platform technologies, the company aims to address the unmet medical needs in the fight against fungal infections and improve patient outcomes worldwide.
SCYNEXIS Inc has achieved several significant milestones. Firstly, the company successfully developed and obtained FDA approval for its revolutionary antifungal drug, ibrexafungerp, which marks a major breakthrough in the treatment of various fungal infections. SCYNEXIS Inc also formed multiple strategic partnerships and collaborations with leading pharmaceutical firms to further advance the research and development of their pipeline products. Additionally, the company has demonstrated strong clinical trial results and gained recognition within the industry for its innovative approach. These milestones solidify SCYNEXIS Inc's position as a key player in the pharmaceutical sector, with a promising future ahead.
SCYNEXIS Inc is primarily present in the United States.
SCYNEXIS Inc is a biotechnology company focused on developing and commercializing innovative therapies for serious and life-threatening fungal infections. Their corporate philosophy revolves around delivering novel solutions to patients in need, ensuring scientific excellence, and maintaining a strong commitment to integrity and accountability. With a vision to transform the treatment landscape, SCYNEXIS Inc values scientific innovation, patient-centricity, collaboration, and continuous improvement. By leveraging their expertise and cutting-edge research, SCYNEXIS Inc strives to provide effective therapies that improve patient outcomes and address critical unmet medical needs in the field of antifungal therapies.
Analysts currently set an average price target of 3.74 USD for the SCYNEXIS stock (median: 4.08 USD), implying -30.0 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the SCYNEXIS stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect SCYNEXIS to generate revenue of 39.19 M USD and earnings per share of -0.05 USD.
Converted at the current exchange rate, the SCYNEXIS share trades at 4.49 EUR (5.22 USD).
The SCYNEXIS share (SCYX) is listed on 4 stock exchanges, including: NASDAQ (SCYX), Frankfurt (135A.F), München (135A.MU), London (0L49.L).
SCYNEXIS Inc is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of infectious diseases and other conditions. The company is headquartered in Jersey City, New Jersey, and also has offices in North Carolina and Massachusetts. SCYNEXIS has three main business areas: research and development, licensing and strategic partnerships, and commercialization of products. In its research and development department, the company uses advanced technologies and innovative approaches to identify, develop, and test new chemical compounds and drug candidates. These drug candidates target serious infectious diseases such as vaginal candidiasis, aspergillosis, and systemic fungal infections, which can potentially be life-threatening. Due to the high development costs and long development times, SCYNEXIS also collaborates with strategic partners to accelerate the development of its product candidates and minimize risk. The company's key partners include leading players in the pharmaceutical industry such as Pfizer and Roche. Another important branch of SCYNEXIS is the licensing of its technologies and product candidates to third parties. Through this licensing, the company aims to monetize its technologies without bearing the high costs of regulatory approval and marketing. Previous licensees of SCYNEXIS include companies such as Allergan and Sanofi. Recently, SCYNEXIS has also started to commercialize its own products. In 2018, the company received approval from the US Food and Drug Administration (FDA) for its first commercial product, Brexafemme® (Ibrexafungerp), an oral medication for the treatment of vaginal candidiasis. Overall, SCYNEXIS focuses on developing products with high medical needs that can also be commercially successful. The company has a strong pipeline of drug candidates that can potentially be life-saving, and it is well positioned to benefit from the growing demand for innovative therapies in the global healthcare industry. The company relies on close collaboration with partners and licensees to minimize risk and accelerate the development of its medications. By commercializing its own products like Brexafemme®, the company has already demonstrated its ability to successfully bring innovative therapies to market and generate long-term growth. Overall, SCYNEXIS' business model is focused on developing innovative therapies and cooperating with partners and licensees to minimize risk and increase the market success of its products. The company is well positioned to benefit from the growing demand for innovative medications in the global healthcare industry and to realize its vision of improving patients' lives through innovative therapies.
The expected revenue of SCYNEXIS is 39.19 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of SCYNEXIS is -2.43 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of SCYNEXIS is currently -104.38. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SCYNEXIS stock.
The price-to-sales ratio (P/S) of SCYNEXIS is currently 6.46. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SCYNEXIS stock.
The Eulerpool Quality Score for SCYNEXIS is 2/10.
The ISIN of SCYNEXIS is US8112922005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of SCYNEXIS is A2P9T4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of SCYNEXIS is SCYX. The ticker symbol is used to trade SCYNEXIS shares on the stock exchange.
SCYNEXIS paid dividends every year for the past 0 years.
SCYNEXIS is assigned to the 'Health' sector.
The dividends of SCYNEXIS are distributed in USD.
SCYNEXIS stock
SCYNEXIS Peer Group
SCYNEXIS Ticker
SCYNEXIS FIGI
All fundamentals and in-depth analysis of SCYNEXIS
Our stock analysis for SCYNEXIS stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SCYNEXIS. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.